AR050960A1 - Uso de un compuesto de 4-bencil-1,3-dihidro-imidazol-2-tiona sustituido o no sustituido para la preparacion de una composicion farmaceutica y dichos compuestos - Google Patents
Uso de un compuesto de 4-bencil-1,3-dihidro-imidazol-2-tiona sustituido o no sustituido para la preparacion de una composicion farmaceutica y dichos compuestosInfo
- Publication number
- AR050960A1 AR050960A1 ARP050104065A ARP050104065A AR050960A1 AR 050960 A1 AR050960 A1 AR 050960A1 AR P050104065 A ARP050104065 A AR P050104065A AR P050104065 A ARP050104065 A AR P050104065A AR 050960 A1 AR050960 A1 AR 050960A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- alkyl
- aryl
- group
- independently selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Abstract
Uso de compuestos de 4-bencil-1,3-dihidro-imidazol-2-tionas sustituidos y no sustituidos de la formula (1) donde n es un entero que oscila entre los valores de 0 a 5; R1 es independientemente seleccionado del grupo formado por alquilo C1-4, alquenilo C2-4, alquinilo C2-4, (CH2)mOR2, (CH2)mNR3R4, (CH2)mCN9, C(O)OR5, (CH2)mSO2R5, arilo, heteroarilo, F, Cl, Br, I, fluoroalquilo C1-4 y de 1 a 9 átomos de F y fluoroalcoxi C1-4 y de 1 a 9 átomos de F, N3 y NO2, dicho heteroarilo contiene de 1 a 3 heteroátomos independientemente seleccionados a partir de O, N y S y dichos grupos arilos y hetearilos se encuantran opcionalmente sustituidos por 1 a 3 radicales seleccionados del grupo formado por alquilo C1-4, alquenilo C2-4, alquinilo C2- 4,es (CH2)mOR2, (CH2)mNR3R4, (CH2)mCN9C(O)OR5, C(O)OR5, (CH2)mSO2R5, fluoroalquilo C1-4 y de 1 a 9 átomos de F, fluoroalcoxi C1-4 y de 1 a 9 átomos de F, N3 y NO2; m es un entero que oscila entre los valores de 0, 1, 2 o 3; R2 es H, alquilo C1-4, C(O)R5, y arilo o heteroarilo que contiene de 1 a 3 heteroátomos independientemente seleccionados de O, N y S y dicho arilo y grupos heteroarilos son opcionalmente sustituidos con 1 a 3 radicales seleccionados del grupo formado por alquilo C1-4, alquenilo C2-4, alquinilo C2-4, (CH2)mOR2, (CH2)mNR3R4, (CH2)mCN9, C(O)OR5, (CH2)mSO2R5, fluoroalquilo C1-4 y de 1 a 9 átomos de F, N3 y NO2; R3 y R4 son independientemente seleccionados del grupo formado por H, alquilo C1-4, C(O)R5 y bencilo; R5 es independientemente H, alquilo C1-4, arilo o heteroarilo que contiene 1 a 3 heteroátomos independientemente seleccionados de O, N y S y dicho arilo y grupos heteroarilo son opcionalmente sustituidos por 1 a 3 radicales seleccionados del grupo formado por alquilo C1-4, alqueniloC2-4, alquinilo C2-4, (CH2)mOR2, (CH2)mNR3R4, (CH2)mC(O)OR5, C(O)OR5, (CH2)mSO2R5, fluoroalquilo C1-4 y de 1 a 9 átomos de F, fluoroalcoxi C1-4 y de 1 a 9 átomos de F, N3 y NO2, para preparar una composicion farmacéutica util para el tratamiento de los dolores cronicos, dolores viscerales, dolores neurofáticos, dolores de cornea, glaucoma, presion intraocular elevada, neuropatologías isquémicas, enfermedades neurodegenerativas, diarreas, congestion nasal, musculos espásticos, diuresis, síndrome de retiro, enfermedades neurodegenerativas, neuropatología optica, isquemia espinal, ataques, deficiencias de memoria y conocimiento, desordenes de déficit de atencion, psicosis, desordenes maníacos, ansiedad, depresion, hipertension, falla corazon congestivo, isquemia cardíaca, artritis, espondilitis, artritis gotoso, osteoartritis, artritis juvenil, enfermedades autoinmunes, eritematosis de lupus, inflamaciones gastrointestinales cronicas, enfermedad de Crohn, gastritis, síndrome del intestino irritable (IBS), dispepsia funcional, colitis ulcerativa o la combinacion de cualquiera de ellas. Reivindicacion 17: Un compuesto util para la preparacion de una composicion farmacéutica de acuerdo al uso de la reivindicacion 1, caracterizado porque se selecciona del grupo formado por los compuestos 1 a 6 que muestran la formula estructural que aparece abajo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61387004P | 2004-09-28 | 2004-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050960A1 true AR050960A1 (es) | 2006-12-06 |
Family
ID=35636664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104065A AR050960A1 (es) | 2004-09-28 | 2005-09-27 | Uso de un compuesto de 4-bencil-1,3-dihidro-imidazol-2-tiona sustituido o no sustituido para la preparacion de una composicion farmaceutica y dichos compuestos |
Country Status (13)
Country | Link |
---|---|
US (3) | US7795292B2 (es) |
EP (1) | EP1797044A2 (es) |
JP (1) | JP4986856B2 (es) |
KR (1) | KR101202066B1 (es) |
CN (1) | CN101044120B (es) |
AR (1) | AR050960A1 (es) |
AU (1) | AU2005290013A1 (es) |
BR (1) | BRPI0516217A (es) |
CA (1) | CA2582071A1 (es) |
MX (1) | MX2007003307A (es) |
NZ (1) | NZ553566A (es) |
TW (1) | TW200616622A (es) |
WO (1) | WO2006036512A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101202066B1 (ko) * | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법 |
WO2008011487A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
KR101023696B1 (ko) * | 2008-08-19 | 2011-03-25 | 충북대학교 산학협력단 | 신규 사이클릭 티오 유레아 유도체, 그의 제법 및 이를 함유한 미백용 조성물 |
JP5938407B2 (ja) | 2010-08-16 | 2016-06-22 | アラーガン、インコーポレイテッドAllergan,Incorporated | α−2Bアドレナリン受容体作動薬を用いて制御性T細胞を活性化する方法 |
CN108346612B (zh) * | 2017-01-25 | 2022-01-25 | 元太科技工业股份有限公司 | 柔性电子器件的制造方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU795462A3 (ru) | 1975-03-14 | 1981-01-07 | Эдьт Дьедьесерведьесети Дьяр (Фирма) | Способ получени тиокарбамидныхпРОизВОдНыХ |
JPS59205366A (ja) * | 1983-04-12 | 1984-11-20 | スミスクライン・ベツクマン・コ−ポレイシヨン | ド−パミン−β−ヒドロキシラ−ゼ抑制物質 |
US4798843A (en) * | 1987-07-09 | 1989-01-17 | Smithkline Beckman Corporation | 2-mercaproimidazole dopamine-β-hydroxylase inhibitors |
US4798834A (en) * | 1987-08-31 | 1989-01-17 | Eli Lilly And Company | Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement |
JPH0667368A (ja) | 1992-08-13 | 1994-03-11 | Fuji Photo Film Co Ltd | 黒白ハロゲン化銀写真感光材料の現像方法 |
ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
PL201704B1 (pl) * | 1996-06-27 | 2009-04-30 | Janssen Pharmaceutica Nv | Pochodna N-[4-(heteroarylometylo)fenylo] heteroaryloaminy, kompozycja farmaceutyczna i sposób wytwarzania pochodnej N-[4-(heteroarylometylo)fenylo] heteroaryloaminy |
WO1999028200A1 (fr) | 1997-11-28 | 1999-06-10 | Mitsubishi Plastics, Inc. | Poignee pour bouteilles en matiere plastique et bouteille en matiere plastique munie de poignee |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
AU744798B2 (en) * | 1997-12-04 | 2002-03-07 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
AU5704000A (en) * | 1999-06-28 | 2001-01-31 | Meiji Seika Kaisha Ltd. | Hydrazone derivatives and pest controllers |
JP2002097310A (ja) | 2000-09-25 | 2002-04-02 | Bridgestone Corp | タイヤ |
JP2002097312A (ja) | 2000-09-26 | 2002-04-02 | Bridgestone Corp | タイヤ |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
EP1453811A2 (en) * | 2001-11-30 | 2004-09-08 | Eli Lilly And Company | Peroxisome proliferator activated receptor agonists |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
KR101202066B1 (ko) * | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법 |
-
2005
- 2005-09-07 KR KR1020077006937A patent/KR101202066B1/ko not_active IP Right Cessation
- 2005-09-07 NZ NZ553566A patent/NZ553566A/en unknown
- 2005-09-07 JP JP2007534620A patent/JP4986856B2/ja not_active Expired - Fee Related
- 2005-09-07 BR BRPI0516217-3A patent/BRPI0516217A/pt not_active IP Right Cessation
- 2005-09-07 MX MX2007003307A patent/MX2007003307A/es active IP Right Grant
- 2005-09-07 CA CA002582071A patent/CA2582071A1/en not_active Abandoned
- 2005-09-07 AU AU2005290013A patent/AU2005290013A1/en not_active Abandoned
- 2005-09-07 WO PCT/US2005/032221 patent/WO2006036512A2/en active Application Filing
- 2005-09-07 CN CN2005800327205A patent/CN101044120B/zh not_active Expired - Fee Related
- 2005-09-07 EP EP05796348A patent/EP1797044A2/en not_active Withdrawn
- 2005-09-20 US US11/232,287 patent/US7795292B2/en not_active Expired - Fee Related
- 2005-09-27 AR ARP050104065A patent/AR050960A1/es not_active Application Discontinuation
- 2005-09-27 TW TW094133558A patent/TW200616622A/zh unknown
-
2010
- 2010-08-03 US US12/849,469 patent/US8178571B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/447,607 patent/US20120196911A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006036512A2 (en) | 2006-04-06 |
TW200616622A (en) | 2006-06-01 |
NZ553566A (en) | 2010-11-26 |
MX2007003307A (es) | 2007-05-16 |
CA2582071A1 (en) | 2006-04-06 |
WO2006036512A3 (en) | 2006-05-04 |
JP4986856B2 (ja) | 2012-07-25 |
US8178571B2 (en) | 2012-05-15 |
BRPI0516217A (pt) | 2008-08-26 |
US20100298395A1 (en) | 2010-11-25 |
CN101044120A (zh) | 2007-09-26 |
US20120196911A1 (en) | 2012-08-02 |
AU2005290013A1 (en) | 2006-04-06 |
KR101202066B1 (ko) | 2012-11-15 |
US20060069142A1 (en) | 2006-03-30 |
JP2008514699A (ja) | 2008-05-08 |
US7795292B2 (en) | 2010-09-14 |
KR20070058533A (ko) | 2007-06-08 |
CN101044120B (zh) | 2011-06-15 |
EP1797044A2 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2318816C2 (ru) | 4-замещенные имидазол-2-тионы и имидазол-2-оны в качестве агонистов альфа2b- и альфа2c- адренергических рецепторов | |
AR051106A1 (es) | Compuesto de 4- (metil ciclico condensado) - imidazol - 2- tiona y su uso para la preparacion de una composicion farmaceutica | |
AR050960A1 (es) | Uso de un compuesto de 4-bencil-1,3-dihidro-imidazol-2-tiona sustituido o no sustituido para la preparacion de una composicion farmaceutica y dichos compuestos | |
AR051108A1 (es) | Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica | |
PE20191153A1 (es) | Moduladores de calpainas y usos terapeuticos de los mismos | |
PE20190260A1 (es) | Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas | |
RU2011131067A (ru) | Стабильные инсектицидные композиции и способы их получения | |
AR051107A1 (es) | Compuesto de 4- (fenilmetil - metil) o 4 (fenilmetil- metil substituido ) - imidazol 2-tiona y su uso para la preparacion de una composicion farmaceutica | |
JP3160297B2 (ja) | ピリミジン誘導体の製造方法 | |
JP2012509314A (ja) | ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法 | |
Wu et al. | Temperature-dependent annuloselectivity and stereochemistry in the reactions of methanesulfonyl sulfene with imines | |
BR112015029714B1 (pt) | Processo para preparar derivados de 4,6-bis(ariloxi)pirimidina | |
JP2020511450A5 (es) | ||
KR960034195A (ko) | 액정으로서의 디-1,3-디옥산 유도체 | |
CN104837822B (zh) | 含氟原子的巯基化合物 | |
US3328395A (en) | 6-halo-2-amino substituted-4-sulfanilamido-pyrimidine compounds | |
US2594309A (en) | Antimalarial agents and method of | |
US3293245A (en) | 2-fluoroalkyl oxazolines and oxazines | |
US2894971A (en) | Polyfluoroalkyl p-toluenesulfonates | |
JPH01106874A (ja) | 光学活性フェニルピリミジン化合物および液晶組成物 | |
JPH06128261A (ja) | 3環性トリアゾロ誘導体の製造方法 | |
JPH0217549B2 (es) | ||
FR3058833B1 (fr) | Procede de fabrication d'une membrane separatrice pour accumulateur | |
JP2015508764A (ja) | クロロアミン類の製造方法 | |
US3053827A (en) | 4-sulfanilamido-2, 6-dihalopyrimidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |